Aran Andrea, Garrigós Laia, Curigliano Giuseppe, Cortés Javier, Martí Mercè
Immunology Unit, Department of Cell Biology, Physiology and Immunology, Institut de Biotecnologia I Biomedicina (IBB), Universitat Autònoma de Barcelona (UAB), 08193 Bellaterra, Spain.
International Breast Cancer Center (IBCC), 08017 Barcelona, Spain.
Cancers (Basel). 2022 Mar 31;14(7):1771. doi: 10.3390/cancers14071771.
T cells play a vital role in the anti-tumoural response, and the presence of tumour-infiltrating lymphocytes has shown to be directly correlated with a good prognosis in several cancer types. Nevertheless, some patients presenting tumour-infiltrating lymphocytes do not have favourable outcomes. The TCR determines the specificities of T cells, so the analysis of the TCR repertoire has been recently considered to be a potential biomarker for patients' progression and response to therapies with immune checkpoint inhibitors. The TCR repertoire is one of the multiple elements comprising the immune system and is conditioned by several factors, including tissue type, tumour mutational burden, and patients' immunogenetics. Its study is crucial to understanding the anti-tumoural response, how to beneficially modulate the immune response with current or new treatments, and how to better predict the prognosis. Here, we present a critical review including essential studies on TCR repertoire conducted in patients with cancer with the aim to draw the current conclusions and try to elucidate whether it is better to encounter higher clonality with few TCRs at higher frequencies, or higher diversity with many different TCRs at lower frequencies.
T细胞在抗肿瘤反应中发挥着至关重要的作用，并且肿瘤浸润淋巴细胞的存在已被证明与几种癌症类型的良好预后直接相关。然而，一些存在肿瘤浸润淋巴细胞的患者并未获得良好的治疗结果。T细胞受体（TCR）决定了T细胞的特异性，因此，TCR库分析最近被认为是预测患者病情进展以及对免疫检查点抑制剂治疗反应的一种潜在生物标志物。TCR库是构成免疫系统的多个要素之一，受到多种因素的制约，包括组织类型、肿瘤突变负荷和患者的免疫遗传学。对其进行研究对于理解抗肿瘤反应、如何利用现有或新的治疗方法有益地调节免疫反应以及如何更好地预测预后至关重要。在此，我们进行了一项批判性综述，纳入了对癌症患者TCR库的重要研究，旨在得出当前结论，并试图阐明是在较高频率下出现少数TCR的高克隆性更好，还是在较低频率下出现许多不同TCR的高多样性更好。
